NCT00964158View on ClinicalTrials.gov

Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)

PHASE3CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

September 10, 2009

Primary Completion Date

November 27, 2010

Study Completion Date

November 27, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

Pandemic influenza vaccine GSK2340272A

Two primary intramuscular (IM) injections and a booster IM injection

Trial Locations (5)

28046

GSK Investigational Site, Madrid

28935

GSK Investigational Site, Móstoles/Madrid

41013

GSK Investigational Site, Seville

48013

GSK Investigational Site, Bilbao

09005

GSK Investigational Site, Burgos

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00964158 - Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A) | Biotech Hunter | Biotech Hunter